Friday, May 16, 2025

South Korean Elementary School in Flames, Estimated Property Damage at $1.12 Million

A fire at Jeseok Elementary School in...

How Seoul Grand Park Lost Its Last North Chinese Leopard and a Beloved Lion

In the first half of 2024, Seoul Grand Park lost two animals named León: a lion in February and the last North Chinese leopard in June.

Washington D.C. Hosts Groundbreaking Industrial Summit with U.S., Japan, and South Korea

The industrial ministers of South Korea, the...

Jin Joong Hwang

Author's Latest

AI Search on Safari: Apple Confirms It’s Exploring ChatGPT and Perplexity

Apple is considering integrating AI search engines into Safari, but Google remains the default due to a lucrative contract.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

A New Era in Precision Oncology—Lunit Unveils 7 AI-Driven Cancer Studies at AACR 2025

Lunit will present AI biomarker studies at AACR 2025, focusing on rare cancers and improving treatment strategies using AI analysis.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

Sandoz: Millions of Patients Denied Access to Affordable Enbrel Alternative

Sandoz has filed an antitrust lawsuit against Amgen to challenge patent practices blocking its biosimilar, Erelzi, from market entry.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Long-Acting HIV Treatment Vocabria + Rekambys Offers New Hope with Just Six Injections a Year

Long-acting HIV treatment Vocabria + Rekambys improves adherence and quality of life, reducing daily pill burden to six injections yearly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.